The Bayer Group continued to grow sales in the second quarter of 2015 and significantly increased earnings. Sales of HealthCare increased by 28.0 percent (Fx & portfolio adj. 8.3 percent) to EUR 5,908 million in the second quarter (Q2 2014: EUR 4,615 million).
Pharmaceutical firms "underinvest" in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published study co-authored by MIT economists. Specifically, drugs to treat late-stage cancers are less costly to develop than drugs for earlier-stage cancers, partly because the late-stage drugs extend people's lives for shorter durations of time.
AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa
Monday, 27 July 2015
AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine. Caprelsa was granted Orphan Drug Designation by the US FDA in 2005 and is currently available in 28 countries for the treatment of aggressive and symptomatic medullary thyroid carcinoma, with global product sales of $48 million in 2014.
Toxin from salmonid fish has potential to treat cancer
Friday, 24 July 2015
Pathogenic bacteria develop killer machines that work very specifically and highly efficiently. Scientists from the University of Freiburg have solved the molecular mechanism of a fish toxin that could be used in the future as a medication to treat cancer. The scientists have now published their research in the journal Nature Communications.
European Commission approves Amgen's new cholesterol-lowering medication Repatha™ (evolocumab)
Thursday, 23 July 2015
Amgen (NASDAQ:AMGN) announced that the European Commission (EC) has granted marketing authorization for Repatha™ (evolocumab), the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol (LDL-C) reduction.
Targeting the strain of bacteria that causes ulcers may help prevent stomach cancer
Wednesday, 22 July 2015
A new review published in the Cochrane Library, indicates that eradicating Helicobacter pylori bacterium - the main cause of stomach ulcers - with a short course of therapy comprising two commonly used medicines may help to reduce the risk of gastric cancer. Stomach, or gastric, cancer is the third most common cause of death from cancer worldwide, and people who are infected with the Helicobacter pylori bacterium are more likely to develop the disease.
Stem cell therapy shows promise in small clinical trial for rare lung disease
Tuesday, 21 July 2015
Canadian researchers have published promising results of the first clinical trial in the world of a genetically-enhanced stem cell therapy for pulmonary arterial hypertension (PAH). This rare and deadly disease mainly affects young women, and is characterized by very high pressure in the arteries supplying blood to the lungs.